Shionogi - Dolutegravir Can Bring ‘Good Times’ Back to Shionogi!
![](/report_cover/5562/shionogi_dolutegravir_can_bring_good_times_back_to_shionogi_en.gif)
Topline data from PhIII SINGLE trial are encouraging and similar outcome from four late stage studies can bring Dolutegravir in forefront of anti-HIV therapy – this is the first drug showing superiority of this extent to current standard of care Atripla (Gilead, FY 11 sales $3.2b); though the competitive landscape is rapidly changing in anti-HIV regime, we expect dolutegravir has potential to cross $2.5b. In this report we have analyzed dolutegravir opportunity in mono-thx and in combination therapy based on data announced and taking the emerging competition into consideration.
COMPANIES MENTIONED
Shionogi
Shionogi